Adherium

The study demonstrated a five-fold reduction in asthma-related hospitalizations observed in patients using Adherium's Smartinhaler.

Researchers plan to recruit 675 adults to investigate the safety and efficacy of three different treatment regimens for mild asthma.

Also the three studies Adherium has conducted have found a 14.9% increase in lung function and a 37% reduction in oral steroid usage.

The New Zealand-based company got $3 million from AstraZeneca with which it recently signed a long-term commercialization agreement.

With Adherium's smartphone-connected device, the medication adherence increases by up to 59% in adults and 180% in children with asthma.